Key result
Application of human cardiac-derived adherent proliferating cells in an acute murine model of Coxsackievirus B3-induced myocarditis reduced cardiac viral load by 5.2-fold and improved left ventricular contractility.
Why the study?
Does application of human cardiac-derived adherent proliferating cells (CAPs) improve viral load and contractility in a murine model of acute Coxsackievirus B3-induced myocarditis?
Does application of human cardiac-derived adherent proliferating cells (CAPs) improve viral load and contractility in a murine model of acute Coxsackievirus B3-induced myocarditis?
Effect estimate: 5.2-fold reduction
p-value: p=<0.05
Human cardiac-derived adherent proliferating cells (CAPs) represent a promising novel cellular therapy that reduces viral load and improves cardiac function in acute viral myocarditis models.
No takes yet. Share an insight, caveat, or question.
CAPs show immunomodulatory promise in animal inflammatory cardiomyopathy models; leaves open human translation pending trials.
Miteva et al. (2011) studied Acute Coxsackievirus B3-induced myocarditis. Human Cardiac-Derived Adherent Proliferating Cells (CAPs) vs. PBS was evaluated on Cardiac viral load (5.2-fold reduction, p=<0.05). Application of human cardiac-derived adherent proliferating cells in an acute murine model of Coxsackievirus B3-induced myocarditis reduced cardiac viral load by 5.2-fold and improved left ventricular contractility.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: